White Paper

Maximizing The Value Of Early Phase Material: Match Your Development And Manufacturing Path To Your IND Milestones

Source: Lonza

By Dr. Raymond Donninger, Senior Director Commercial Development, Early Development Services, Lonza Biologics


Reaching IND stage is a major milestone for biopharmaceutical companies. The drug development journey is long, expensive, resource straining, and risky due to high attrition rates. A large amount of data must be generated, collected, interpreted and correctly integrated for the First-in-Human (FIH)-enabling data package. Many of these steps are carried out in parallel but rely on the results from previous steps for an optimal outcome. For example, not performing an optimal molecule de-risking and optimization program early in drug development can result in safety, efficacy, and/or manufacturability issues later in development, resulting in higher development costs to go back and rectify these issues and development time that is likely to be significantly longer.

Discover how to maximize the value of early phase material and match your development path to your IND milestones.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online